NYSE:ENZ

Enzo Biochem - ENZ Stock Forecast, Price & News

$1.35

-0.05 (-3.57%)

(As of 02/8/2023 12:00 AM ET)

Add

Compare

Today's Range: $1.34
▼
$1.47
50-Day Range: $1.16
▼
$1.98
52-Week Range: $1.11
▼
$3.51

Volume: 59,350 shs
Average Volume: 56,218 shs
Market Capitalization: $65.77 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Institutional Ownership

Enzo Biochem MarketRank™ Forecast

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Bearish
0.93% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.06
Based on 3 Articles This Week
Insider Trading: Acquiring Shares
$213,520 Bought Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.26 out of 5 stars

Medical Sector

989th out of 1,026 stocks

Medical Laboratories Industry

22nd out of 24 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Enzo Biochem.

2.0

Short Interest

Percentage of Shares Shorted
0.93% of the float of Enzo Biochem has been sold short.
Short Interest Ratio / Days to Cover
Enzo Biochem has a short interest ratio ("days to cover") of 5.1.
Change versus previous month
Short interest in Enzo Biochem has recently increased by 0.99%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Enzo Biochem does not currently pay a dividend.
Dividend Growth
Enzo Biochem does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ENZ.

2.3

News and Social Media Coverage

News Sentiment
Enzo Biochem has a news sentiment score of 0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Enzo Biochem this week, compared to 1 article on an average week.
Search Interest
3 people have searched for ENZ on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Enzo Biochem insiders have bought more of their company's stock than they have sold. Specifically, they have bought $213,520.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
15.50% of the stock of Enzo Biochem is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
50.56% of the stock of Enzo Biochem is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Enzo Biochem is -2.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Enzo Biochem is -2.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Enzo Biochem has a P/B Ratio of 1.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Enzo Biochem (NYSE:ENZ) Stock

Enzo Biochem, Inc. is an integrated diagnostics, clinical lab, and life sciences company, which focuses on delivering and applying advanced technology capabilities to produce affordable reliable products and services that enable customers to meet their clinical needs. It operates through the following segments: Products, Clinical Services, and Therapeutics. The Products segment develops, manufactures, and markets products to research and pharmaceutical customers. The Clinical Services segment provides diagnostic services to the health care community. The Therapeutics segment conducts research and development activities for therapeutic drug candidates. The company was founded by Elazar Rabbani, Barry W. Weiner and Shahram K. Rabbani in 1976 and is headquartered in New York, NY.

Receive ENZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enzo Biochem and its competitors with MarketBeat's FREE daily newsletter.

ENZ Stock News Headlines

February 9, 2023 | marketwatch.com

Oxidative Stress Assay Market Size, Status, Global outlook 2023 To 2029

February 8, 2023 | marketwatch.com

Oxidative Stress Assays Market Research Report 2023 by Size, Share, Product Type, Application, Region and Global Forecast to 2028

February 8, 2023 | Altimetry (Ad)

Massive “Heist” Could Sweep U.S. Banks in 2023

Wall Street professor warns FBI and U.S. Pentagon about a banking scheme that could soon cause a financial panic in all 50 states

February 8, 2023 | marketwatch.com

Clinical Reference Laboratory Services Market Analysis Report 2023 Along with Statistics Figures, till 2028

February 7, 2023 | marketwatch.com

Rhodamine 123 Market Share Likely to Grow At a CAGR

February 1, 2023 | americanbankingnews.com

Enzo Biochem, Inc. (NYSE:ENZ) Major Shareholder Buys $16,520.00 in Stock

February 1, 2023 | americanbankingnews.com

Enzo Biochem (NYSE:ENZ) Coverage Initiated by Analysts at StockNews.com

January 29, 2023 | marketwatch.com

Non-Radioactive Nucleic Acid Labeling Product Market Size, Sales, CAGR And Competition Data from 2023 To 2028 with Top Countries Data

February 8, 2023 | Altimetry (Ad)

Massive “Heist” Could Sweep U.S. Banks in 2023

Wall Street professor warns FBI and U.S. Pentagon about a banking scheme that could soon cause a financial panic in all 50 states

January 23, 2023 | nasdaq.com

James Wolf Ups Stake in Enzo, May Seek Board Seat

January 18, 2023 | reuters.com

ENZ.DF - | Stock Price & Latest News | Reuters

January 16, 2023 | benzinga.com

Biomarkers Market is expected to grow from USD 66.6 billion in 2022 to USD 183.42 billion by 2030 : GreyViews

December 17, 2022 | marketwatch.com

Clinical Reference Laboratory Services Market 2023-2028 : Leading Growth Drivers, Emerging Audience, Segments, Industry Sales, Profits & Analysis

December 16, 2022 | finance.yahoo.com

Enzo Biochem, Inc. (NYSE:ENZ) Q1 2023 Earnings Call Transcript

December 13, 2022 | seekingalpha.com

Enzo Biochem, Inc. (ENZ) Q1 2023 Earnings Call Transcript

December 13, 2022 | finanznachrichten.de

Enzo Biochem, Inc.: Enzo Biochem Reports First Quarter Fiscal Year 2023 Financial Results and Provides Business Update

December 13, 2022 | marketwatch.com

Oligomycin Market 2023 : Size (value & volume) by Company, Key Regions, Type, and Application 2028

December 13, 2022 | marketwatch.com

Quizartinib Market 2023 : Industry Analysis, Opportunities, Technology, Top Players and Growth Forecast 2028

December 12, 2022 | finance.yahoo.com

Enzo Biochem Reports First Quarter Fiscal Year 2023 Financial Results and Provides Business Update

December 7, 2022 | finance.yahoo.com

Enzo Biochem, Inc. to Report First Quarter Fiscal 2023 Financial Results and Business Update on Monday, December 12th

November 18, 2022 | finance.yahoo.com

As Enzo Biochem, Inc. (NYSE:ENZ) drops to US$100m market cap, insiders might rethink their US$3.1m stock purchase earlier this year

November 8, 2022 | finance.yahoo.com

Enzo Biochem, Inc. Announces Date of Annual Shareholders’ Meeting

October 24, 2022 | nasdaq.com

Shareholders in Enzo Biochem (NYSE:ENZ) are in the red if they invested five years ago

October 20, 2022 | finance.yahoo.com

Enzo Biochem, Inc. Appoints Patricia Eckert, CPA as Interim CFO

October 17, 2022 | finance.yahoo.com

The past five years for Enzo Biochem (NYSE:ENZ) investors has not been profitable

October 15, 2022 | finanznachrichten.de

Enzo Biochem, Inc.: Enzo Biochem Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update

October 14, 2022 | finance.yahoo.com

Enzo Biochem Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ENZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enzo Biochem and its competitors with MarketBeat's FREE daily newsletter.

ENZ Company Calendar

Last Earnings: 12/12/2022
Today: 2/08/2023
Next Earnings (Estimated): 3/13/2023
Fiscal Year End: 7/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Medical laboratories
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSE:ENZ
CUSIP: N/A
CIK: 316253
Web: www.enzo.com
Phone: (212) 583-0100
Fax: 212-679-7999
Employees: 451
Year Founded: 1976

Profitability

EPS (Most Recent Fiscal Year): ($0.54)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-18,260,000.00
Net Margins: -26.89%
Pretax Margin: -26.89%
Return on Equity: -38.65%
Return on Assets: -22.26%

Debt

Debt-to-Equity Ratio: 0.09
Current Ratio: 1.84
Quick Ratio: 1.19

Sales & Book Value

Annual Sales: $107.07 million
Price / Sales: 0.61
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.12 per share
Price / Book: 1.21

Miscellaneous

Outstanding Shares: 48,720,000
Free Float: 41,168,000
Market Cap: $65.77 million
Optionable: Optionable
Beta: 0.87

Social Links

Key Executives

Hamid Erfanian
Chief Executive Officer & Director

Kara Cannon
Chief Operating Officer

Patricia Eckert
Chief Financial Officer

Dieter Schapfel
Chief Medical Director

Matthew Kupferberg
Secretary & General Counsel

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ENZ Stock - Frequently Asked Questions

How have ENZ shares performed in 2023?: Enzo Biochem's stock was trading at $1.43 at the start of the year. Since then, ENZ stock has decreased by 5.6% and is now trading at $1.35.
View the best growth stocks for 2023 here.
Are investors shorting Enzo Biochem?: Enzo Biochem saw a increase in short interest in the month of December. As of December 30th, there was short interest totaling 344,100 shares, an increase of 9.1% from the December 15th total of 315,300 shares. Based on an average trading volume of 66,600 shares, the short-interest ratio is currently 5.2 days. Currently, 1.0% of the shares of the company are short sold.
View Enzo Biochem's Short Interest.
When is Enzo Biochem's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, March 13th 2023.
View our ENZ earnings forecast.
How were Enzo Biochem's earnings last quarter?: Enzo Biochem, Inc. (NYSE:ENZ) posted its quarterly earnings results on Monday, December, 12th. The medical research company reported ($0.18) earnings per share (EPS) for the quarter. The medical research company had revenue of $18.28 million for the quarter. Enzo Biochem had a negative net margin of 26.89% and a negative trailing twelve-month return on equity of 38.65%.
What other stocks do shareholders of Enzo Biochem own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Enzo Biochem investors own include OneLife Technologies (OLMM), Gilead Sciences (GILD), OPKO Health (OPK), Teva Pharmaceutical Industries (TEVA), Inovio Pharmaceuticals (INO), AbbVie (ABBV), Pfizer (PFE), Advanced Micro Devices (AMD), Amarin (AMRN) and Micron Technology (MU).

What is Enzo Biochem's stock symbol?: Enzo Biochem trades on the New York Stock Exchange (NYSE) under the ticker symbol "ENZ."
Who are Enzo Biochem's major shareholders?: Enzo Biochem's stock is owned by many different institutional and retail investors. Top institutional shareholders include Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bradley Louis Radoff, David Bench, Discovery Fund Lp Harbert, Hamid Erfanian, James G Wolf, Kara Cannon and Peter J Iv Clemens.
View institutional ownership trends.
How do I buy shares of Enzo Biochem?: Shares of ENZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Enzo Biochem's stock price today?: One share of ENZ stock can currently be purchased for approximately $1.35.
How much money does Enzo Biochem make?: Enzo Biochem (NYSE:ENZ) has a market capitalization of $65.77 million and generates $107.07 million in revenue each year. The medical research company earns $-18,260,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis.
How many employees does Enzo Biochem have?: The company employs 451 workers across the globe.
How can I contact Enzo Biochem?: Enzo Biochem's mailing address is 527 Madison Ave., New York NY, 10022. The official website for the company is www.enzo.com. The medical research company can be reached via phone at (212) 583-0100, via email at ir@enzo.com, or via fax at 212-679-7999.

This page (NYSE:ENZ) was last updated on 2/9/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Enzo Biochem - ENZ Stock Forecast, Price & News

Enzo Biochem MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Enzo Biochem (NYSE:ENZ) Stock

ENZ Stock News Headlines

ENZ Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

ENZ Stock - Frequently Asked Questions

Overall MarketRank^™